1 Title: Study Pre-protocol for "BronchStart - The Impact of the COVID-19 Pandemic on the

2 Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a

3 Multi-Centre Prospective Observational Cohort Study"

Authors: Thomas C. Williams^{1*}, Mark D Lyttle^{2.3}, Steve Cunningham^{4,5}, Ian Sinha^{6,7}, Olivia
Swann^{8,9}, Abigail Maxwell-Hodkinson¹⁰ & Damian Roland^{11,12} on behalf of the Paediatric
Emergency Research in the UK and Ireland (PERUKI)¹³

Affiliations: ¹Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; 7 8 ²Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK; ³Emergency Department, Bristol Royal Hospital for Children, Bristol, UK; ⁴Department of 9 Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, 10 Edinburgh, UK; ⁵ Centre for Inflammation Research, University of Edinburgh, Edinburgh, 11 UK: ⁶University of Liverpool, UK: ⁷Alder Hey Children's Hospital, Liverpool, UK: 12 ⁸Department of Child Life and Health, University of Edinburgh, Edinburgh, UK; 13 ⁹Department of Paediatric Infectious Diseases and Immunology, Royal Hospital for Children, 14 Glasgow, UK; ¹⁰University of Liverpool Medical School, Liverpool, UK; ¹¹Paediatric 15 Emergency Medicine Leicester Academic (PEMLA) Group, Leicester Royal Infirmary, 16 Leicester, UK, ¹²Sapphire Group, Health Sciences, University of Leicester, Leicester, UK; 17 ¹³PERUKI Site Leads are listed in Supplementary File 1. 18

*Corresponding Author: Thomas C Williams, Institute of Genetics and Cancer, University
of Edinburgh, Crewe Road South EH4 2XU [Thomas.Christie.Williams@ed.ac.uk]

21 **Protocol Version: 1**

22

23

24 Abstract

25 Background

Bronchiolitis (most frequently caused by Respiratory Syncytial Virus; RSV) is a common 26 27 winter disease predominantly affecting children under one year of age. It is a common reason 28 for presentations to an Emergency Department (ED) and frequently results in hospital 29 admission, contributing to paediatric units approaching or exceeding capacity each winter. 30 During the SARS-CoV-2 pandemic, the circulation of RSV was dramatically reduced in the 31 United Kingdom and Ireland. Evidence from the Southern Hemisphere and other European 32 countries suggests that as social distancing restrictions for SARS-CoV-2 are relaxed, RSV 33 infection returns, causing delayed or even summer epidemics, with different age distributions.

34 Study question

The ability to track, anticipate and respond to a surge in RSV cases is critical for planning acute care delivery. There is an urgent need to understand the onset of RSV spread at the earliest opportunity. This will influence service planning, to inform clinicians whether the population at risk is a wider age range than normal, and whether there are changes in disease severity. This information is also needed to inform decision on the timing of passive immunisation of children at higher risk of hospitalisation, intensive care admission or death with RSV infection, which is a public health priority.

42 Methods and likely impact

This multi-centre prospective observational cohort study will use a well-established research network (Paediatric Emergency Research in the UK and Ireland, PERUKI) to report in real time cases of RSV infection in children aged under two years, through the collection of essential, but non-identifying patient information. Forty centres will gather initial data on age, index of multiple deprivation quintile, clinical features on presentation, and co-morbidities. Each case will be followed up at 7 days to identify treatment, viral diagnosis and outcome. Information be released on a weekly basis and used to support clinical decision making.

50 Keywords

51 COVID-19; Respiratory Syncytial Virus; Bronchiolitis; Infants; Children; Palivizumab

52

53 Main body

54 Introduction

Non-pharmaceutical interventions (NPIs) implemented to slow or eliminate the spread of 55 SARS-CoV-2 have also had dramatic off-target consequences on transmission of other 56 respiratory viruses, in particular Respiratory Syncytial Virus (RSV) in children. RSV 57 infection can cause a clinical syndrome termed bronchiolitis, most commonly in infants under 58 59 one year of age, and lower respiratory infection associated with wheeze in older children, typically under two years of age. In a typical year in England, RSV bronchiolitis causes 60 61 significant morbidity, leading to an estimated 36,028 annual admissions for RSV, mainly in infants under 1 year of age;¹ every year 0.1% of all infants under 1 are admitted to paediatric 62 intensive care units (PICUs) with a diagnosis of bronchiolitis.² In the years preceding 63 64 2020/21, RSV infections in the United Kingdom and Ireland saw consistent seasonal peaks in infection and hospitalisation, with cases generally starting to rise in September, peaking in 65 November/December, and falling to summer levels by April.¹ As such, when lockdown 66 67 measures were implemented during the early spring of 2020, the RSV season was already in recession in the Northern hemisphere and no clear impact was seen on RSV disease burden. 68 69 However, in the corresponding Southern Hemisphere winter of 2020, the NPIs led to 70 dramatically reduced cases and admissions of paediatric RSV and influenza in Australia,³ New Zealand,⁴ Chile and South Africa.⁵ An associated reduced rate of admissions to 71 Paediatric Intensive Care Unit (PICU) across South America, mainly driven by a reduction in 72 respiratory diagnoses, was also observed.⁶ 73

74

75 Hierarchical variance of NPIs over time have interrupted transmission of some, but not all, respiratory viruses.⁷ In the United Kingdom, test positivity for RSV in the Respiratory 76 77 DataMart system has remained at less than 1% throughout the winter of 2020/21 (last data 11 April 2021).⁸ Conversely, rhinovirus infections continued throughout the Southern and 78 Northern Hemisphere winter seasons.^{8,9} A typical annual spike in rhinovirus infections in 79 children was observed with the return to schools in England in September 2020,8 and PICUs 80 saw ongoing admissions for rhinovirus induced wheeze and bronchiolitis in the 81 82 autumn/winter of 2020 despite lockdown measures [NHS Lothian data, unpublished].

83

Both observational and modelling studies suggest that RSV will arise out of season in the
Northern hemisphere and may have a greater clinical impact.¹⁰ Four Australian states, which

after an initial lockdown imposed few physical distancing measures with re-opened schools, have now experienced delayed annual RSV epidemic peaks. The delayed peak in Western Australia, where infections rates surged during local Spring-Summer (September-December), was associated with even higher case rates than normally seen during winter, despite no change in testing practices.¹¹ Some European countries such as France have already seen evidence of a delayed RSV season, with all French regions now having reported bronchiolitis case rates at epidemic levels.¹²

93

94 From a clinical perspective, it is not possible to distinguish the viral aetiology of lower 95 respiratory tract infection, with the exception of greater probability by season of infection. 96 With the uncoupling of RSV and seasonality observed as an impact of NPIs, there is an 97 urgent requirement to track RSV infection for season onset and to observe the impact on a 98 larger unexposed at risk population. It is likely that when RSV returns to the United 99 Kingdom and Ireland in 2021 it will not follow its usual predictable seasonal pattern, 100 particularly if lockdown measures are relaxed rapidly as SARS-CoV-2 immunisation 101 coverage increases. Reasons why RSV might display unusual disease dynamics include a 102 lack of circulation in the general population leading to a reduction of transplacental 103 antibodies and passive immunity for neonates, and the fact that children born after February 104 2020 will most likely not have been exposed to circulating RSV, thus reducing adaptive 105 immune response to the virus when encountered. RSV infection is also associated with 106 recurrent wheeze as a longer-term post infectious morbidity. A higher proportion of children 107 affected by RSV may increase the subsequent healthcare burden of post infectious wheeze 108 giving a much longer-term burden on health services.

109

110 The objective of this study is to monitor RSV disease in children under two years of age 111 attending emergency departments across the UK and Ireland and examine the impact on 112 timing, age and severity of clinical presentations as NPI restrictions are reduced throughout 113 the UK and Ireland in 2021.

114

115 Study Protocol

This protocol is structured in keeping with the principles of the STROBE statement (strobe-statement.org/).

118 *How the sample is to be selected*

119 A national multi-centre prospective observational cohort study will be carried out through the 120 PERUKI (Paediatric Emergency Research in the UK and Ireland) Network¹³ with forty 121 departments having committed to participating in the study. All children meeting the 122 inclusion criteria below will be eligible.

123 Inclusion criteria

124 Children under two years of age presenting to participating emergency departments with 125 clinical features of bronchiolitis (cough, tachypnoea or chest recession, and wheeze or 126 crackles on chest auscultation)¹⁴ or a first episode of acute viral wheeze.

127 Exclusion criteria

128 Children with previous episodes of wheeze responsive to bronchodilator, suggesting an 129 underlying diagnosis of recurrent wheeze of early childhood.

130 Data collection

We will collect data at two time points: baseline (date of presentation to a participating ED)and seven days later.

133 Clinicians identifying a case for inclusion will keep a local log of participants that contain 134 patient identifiable characteristics cross referenced to a study number. The study number 135 alone is used in all communication/data entry with the study team. An email after 7 days to 136 the submitting clinician will prompt data entry at this point.

Anonymised data will be entered to a secure online database (REDCap data capture tool)^{15,16}
(see below), by clinicians providing acute care within the ED.

139 Variables to be measured

At baseline, data including patient demographics, presenting characteristics, acuity, investigations and treatments will be obtained (see Supplementary File 2), as will data on the number of siblings and travel. An external link will enable clinicians to enter a full postcode derived index of multiple deprivation score for database entry.

144 At 7 days data will include the child's ultimate outcome (discharged or admitted), highest 145 acuity dependency (the ward they were placed on if admitted: Normal, High Dependency or

Intensive Care), whether care is ongoing, patient was discharged or died and (if obtained)what viruses were identified by PCR (see Supplementary File 3).

- 148 RSV status will be identified by either Nasopharyngeal Aspirate (NPA) (a) point of care
 149 testing (rapid viral testing where available) at baseline presentation to ED, or (b) by
 150 laboratory PCR testing, if either is performed as part of standard care.
- 151 Sample size calculation

152 This is a convenience sample cohort study and as such a sample size is not calculated. 153 However, the most recent bronchiolitis peak in France (epidemiological week 13, to 8 April 154 2021), involved 2,433 emergency department (ED) attendances and 953 hospital admissions 155 in children under the age of 2 years, with a total of $\sim 16,000$ ED attendances and $\sim 6,000$ admissions since the start of 2021.¹² The combined population of the United Kingdom and 156 157 Ireland is 72 million, roughly equivalent to that of France (67 million). The PERUKI sites 158 already enrolled in this study are estimated to provide care for 25 % of the total paediatric 159 population, and if a similar trend is seen to France we would therefore expect to recruit 4,000 160 infants and children in the build up to the peak of an RSV epidemic. By site this would be a 161 mean of ~ 100 patients over 3 months, or approximately a patient a day per site. Previous 162 PERUKI surveillance studies have recruited > 1,000 patients in short time scales (1-2) 163 months).

- 164 Study registration
- 165 The trial will be prospectively registered on ISCRTN Registry (https://www.isrctn.com/).
- 166 Primary outcomes to be measured, as well as a list of secondary outcomes
- 167 *Primary outcome*
- 168 To report the timing, frequency and clinical severity of RSV infection in children under two 169 years of age presenting to hospitals in the UK and Ireland.
- 170 Secondary outcomes
- i. To report the excess morbidity of clinical presentations at ED with respiratory disease
 by inclusion criteria by month of presentation (compared to published literature/health
 data sources).
- 174 ii. To report the geographical timing and spread of RSV infection across the UK.

175	iii.	To identify differences in severity of illness and patient population affected by RSV	
176		in relation to typical seasonal ranges in the published literature.	
177	iv.	To provide data to support and corroborate current RSV surveillance systems (i.e.	
178		Respiratory Datamart https://www.gov.uk/government/statistics/national-flu-and-	
179		covid-1 9-surveillance-reports) and the Emergency Department Syndromic	
180		Surveillance System (EDSSS).	
181		(https://www.gov.uk/government/publications/emergency-department- weekly-	
182		bulletins-for-2021).	
183	v.	To provide data to support decision making by government agencies (Joint	
184		Committee on Vaccination and Immunisation) in relation to the prescription of out of	
185		season Palivizumab for high risk children.	
186	vi.	To provide data to support estimates of potential longer-term impact of changes in	
187		severity of illness and patient populations on health (long term recurrent wheeze) and	
188		associated healthcare resources.	
189	9 Data analysis and statistical plan		
190	i.	Demographics, regional frequencies, incidence estimates and logistic regression will	
191		be performed according to a Statistical Analysis Plan (SAP) in place prior to full data	
192		analysis. This will include:	
193	ii.	Descriptive statistics	
194		a. Weekly incidence (broken down nationally and regionally) calculated for	
195		population at risk for each Emergency Department.	
196		b. Median age, co-morbidities, index of multiple deprivation, presenting features	
197		of recruited patients, compared to previous population studies to identify if	
198		similar age, spectrum of co-morbidities and presenting clinical features to	
199		previous epidemics.	
200		c. Proportion of RSV vs non-RSV of those tested.	
201	iii.	Identification of risk factors for severe disease	
202		a. A number of metrics will be examined as proxy measures for severity	
203		including:	
204		i. Median saturations in air at presentation and frequency of attendance	
205		with $SpO_2 < 94\%$ or $< 92\%$ in room air.	
206		ii. Median respiratory rate (with reference to age as per Paediatric Early	
207		Warning Score) at presentation. ¹⁷	

- 208 iii. Blood gas composition (median H+ and pCO2 measurements) at
 209 presentation.
- iv. Proportion of children admitted to hospital and of those the proportion
 admitted to standard care / HDU / PICU.
- v. Proportion of children requiring respiratory support (supplementary oxygen, high flow oxygen, CPAP, BiPAP or invasive ventilation).
 - vi. Length of stay.
- b. Multivariate logistic regression analyses using random effects model
 (recruiting site, availability of on-site PICU facility) to examine risk factors
 for hospitalisation, level of ventilatory support and PICU admission. Risk
 factors will be compared to predictors of severe disease published in
 population studies previously.
- 220 *iv.* Spatio-temporal dynamics of the 2021 epidemic
- 221 222

214

a. Travel histories will be used to identify whether RSV is seeded into community in a number of separate introduction events, or spreads locally.

223 Details of any ethical issues relating to the study (and of the ethical approval received)

224 This prospective observational surveillance study needs to be able to rapidly collate data that 225 will enable other researchers and health services to make informed decisions about the extent of any RSV surge. For this reason, and the fact that the data being obtained is already 226 227 obtained as part of the clinical record, we will not be asking for consent from families and 228 carers. The clinician will only enter data regarding the outcomes of the child and no 229 identifying information will be recorded. The patient's study number will be linked to the 230 local hospital number to allow outcome data to be retrieved. This information will be held by 231 the recruiting site only in secure research lockers in each Emergency Department and only 232 available to appropriately trained staff or research nurses.

None of the data recorded centrally by the study team will mean the patient is identifiable, and there are no specific details recorded that would make it possible to determine any individual child by proxy. This approach has been successfully adopted in other rapidly deployed studies the authors have been involved in. The security of the REDCap system we are using to collate data will add additional data protection safeguards.

The study will be submitted for Integrated Research Application System (IRAS) approval
with University Hospitals of Leicester NHS Trust as the Study Sponsor, IRAS ID 297802.

240 Data input, storage and management

241 Anonymised data will be entered using the validated online data entry software REDCap. 242 (Research Electronic Data Capture tools) following the clinical report forms provided in the 243 appendix (Supplementary Files 2 and 3). This software (REDCap) is hosted on the University 244 Hospitals Bristol and Weston NHS Foundation Trust (UHBW) secure server, accessible on 245 the Health and Social Care Network (HSCN) that is managed by NHS Digital. All research 246 data reside within the hosting institution, and there will be a data transfer agreement made 247 between University Hospitals of Leicester NHS Trust, Edinburgh University and University 248 Hospitals Bristol and Weston NHS Foundation Trust in order to allow transfer of data on 249 completion of data entry and cleaning. Processing of data will be undertaken on instruction of 250 the Data Controller. The study Sponsor organisation (University Hospitals of Leicester NHS) 251 Trust) will be the Data Controller throughout, and University Hospitals Bristol and Weston 252 NHS Foundation Trust will have Joint Controllership for the duration of data entry and 253 cleaning. REDCap uses a granular security model so that users can only review the data they 254 have been explicitly authorised to access. REDCap also provides a comprehensive log/audit 255 feature that records all individual changes with a date/time stamp and a change owner. Data 256 that are captured and stored will only be available via the information technology systems 257 linked to the HSCN which is the current validated system used by NHS Trusts to share and 258 store patient information.

259

260 Plans for dissemination of the study outcome (including the associated data) once completed.

- 261 Data will be presented in:
- 262 i. Data submissions to the regulatory authorities and local study teams, including an263 interactive online dashboard.
- 264 ii. Conference presentations.
- 265 iii. Peer reviewed scientific journals.
- iv. Collaboration with educational websites with international social media reach
 (www.dontforgetthebubbles.com).
- v. Engagement with the RSV patient network, part of the RESCEU Consortium
 (http://resc-eu.org/).
- 270 Conclusions

There is an urgent need to better understand the effects of non-pharmaceutical interventions on the transmission and disease dynamics of Respiratory Syncytial Virus, a major cause of morbidity in infants in the United Kingdom. BronchStart is a multi-centre observational study embedded within the PERUKI network which will inform the immediate clinical response to a delayed RSV peak, improve our understanding of how RSV is seeded and spreads within the United Kingdom, and inform the implementation of future RSV immunisation campaigns.

277 **Ethics policies**

The study protocol has been submitted to Integrated Research Application System; in view of the urgency needed to take this project forward, and the fact that no patient identifiable information will be collected, we believe it to be exempt from Research Ethics Committee (REC) Review. This is also in keeping with the Control of Patient Information Notice (Covid-19 – Notice under Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002) last reviewed 3rd February 2021.

284 Data availability

- As this is a study protocol no data are yet available. Once available, anonymised, non-patient
- identifiable data will be stored on a RedCap server hosted by University of West of England,
- 287 Bristol, United Kingdom (See Data input, storage and management).

288 Author contributions

- Williams TC: Conceptualization, Methodology, Writing Original Draft Preparation,
 Writing Review & Editing
- 291 Lyttle MD: Conceptualization, Methodology, Project Administration, Software, Writing -
- 292 Original Draft Preparation, Writing Review & Editing
- 293 Cunningham S: Conceptualization, Methodology, Project Administration, Writing Original
- 294 Draft Preparation, Writing Review & Editing
- Sinha I: Conceptualization, Methodology, Writing Original Draft Preparation, Writing –
 Review & Editing
- 297 Swann O: Conceptualization, Methodology, Writing Original Draft Preparation, Writing –
- 298 Review & Editing
- 299 Maxwell-Hodkinson A : Conceptualization, Methodology, Writing Review & Editing

- 300 Roland D: Conceptualization, Methodology, Project Administration, Writing Original Draft
- 301 Preparation, Writing Review & Editing
- 302 PERUKI Site Leads: Conceptualization, Writing Review & Editing
- 303

304 Competing Interests

305 No competing interests were disclosed.

306 Grant Information

307 Dr. Williams is the recipient of a Wellcome Trust Award [204802/Z/16/Z].

308 Acknowledgements

- 309 The authors would like to thank Mai Bacquedano for technical support in the launch of the
- 310 REDCap survey tool and ongoing data management.

311 Supplementary material

- 312 Supplementary File 1 lists the PERUKI investigators who will be coordinating local data 313 entry.
- Supplementary File 2 and 3 show the full questionnaires to be completed by clinicians/researchers, including the logic branching trees for questions asked.

316 **References**

- 1 Lewis KM, De Stavola B, Hardelid P. Geospatial and seasonal variation of
- bronchiolitis in England: a cohort study using hospital episode statistics. *Thorax* 2020; **75**: 262–268.
- Green CA, Yeates D, Goldacre A, *et al.* Admission to hospital for bronchiolitis in
 England: Trends over five decades, geographical variation and association with
 perinatal characteristics and subsequent asthma. *Arch Dis Child* 2016; **101**: 140–6.
- Britton PN, Hu N, Saravanos G, *et al.* COVID-19 public health measures and
 respiratory syncytial virus. *Lancet Child Adolesc Heal* 2020; 4: e42–3.
- Huang QS, Wood T, Jelley L, *et al.* Impact of the COVID-19 nonpharmaceutical
 interventions on influenza and other respiratory viral infections in New Zealand. *Nat*

327		<i>Commun</i> 2021; 12 : 1–7.
328	5	Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased Influenza Activity During
329		the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020.
330		MMWR Morb Mortal Wkly Rep 2020; 69: 1305–9.
331	6	Vásquez-Hoyos P, Diaz-Rubio F, Monteverde-Fernandez N, et al. Reduced PICU
332		respiratory admissions during COVID-19. Arch Dis Child 2020; 0: archdischild-2020-
333		320469.
334	7	Williams TC, MacRae C, Swann O V, et al. Indirect effects of the COVID-19
335		pandemic on paediatric healthcare use and severe disease: a retrospective national
336		cohort study. Arch Dis Child 2021; 0: archdischild-2020-321008.
337	8	Public Health England. Weekly national Influenza and COVID-19 surveillance report.
338		2021; published online May 15.
339		https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachmen
340		t_data/file/978131/Weekly_Flu_and_COVID-19_report_w15.pdf (accessed April 16,
341		2021).
342	9	Nicolaides Pathology S. Respiratory Virus Report 2020. 2020.
342 343	9 10	Nicolaides Pathology S. Respiratory Virus Report 2020. 2020. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of
343		Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of
343 344		Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic
343 344 345	10	Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117 : 30547–53.
343 344 345 346	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of
343 344 345 346 347	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of
343 344 345 346 347 348	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021;
343 344 345 346 347 348 349	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021; published online Feb 17. DOI:10.1093/cid/ciaa1906.
343 344 345 346 347 348 349 350	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021; published online Feb 17. DOI:10.1093/cid/ciaa1906. Sante Publique France. Bulletin épidémiologique bronchiolite, semaine 14. Saison
343 344 345 346 347 348 349 350 351	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021; published online Feb 17. DOI:10.1093/cid/ciaa1906. Sante Publique France. Bulletin épidémiologique bronchiolite, semaine 14. Saison 2020-2021. 2021. https://www.santepubliquefrance.fr/maladies-et-
343 344 345 346 347 348 349 350 351 352	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021; published online Feb 17. DOI:10.1093/cid/ciaa1906. Sante Publique France. Bulletin épidémiologique bronchiolite, semaine 14. Saison 2020-2021. 2021. https://www.santepubliquefrance.fr/maladies-et- traumatismes/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-
343 344 345 346 347 348 349 350 351 352 353	10	 Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. <i>Proc Natl Acad Sci</i> 2020; 117: 30547–53. Foley DA, Yeoh DK, Minney-Smith CA, <i>et al.</i> The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019–Related Public Health Measures. <i>Clin Infect Dis</i> 2021; published online Feb 17. DOI:10.1093/cid/ciaa1906. Sante Publique France. Bulletin épidémiologique bronchiolite, semaine 14. Saison 2020-2021. 2021. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/bronchiolite/documents/bulletin-national/bulletin-epidemiologique-bronchiolite-semaine-14saison-2020-2021

357		multicentre research. Arch Dis Child 2014; 99: 602–3.
358	14	NICE. 1 Recommendations Bronchiolitis in children: diagnosis and management
359		Guidance NICE. https://www.nice.org.uk/guidance/ng9/chapter/1-
360		Recommendations#assessment-and-diagnosis (accessed April 2, 2021).
361	15	Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an
362		international community of software platform partners. J Biomed Inform 2019; 95.
363		DOI:10.1016/j.jbi.2019.103208.
364	16	Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
365		data capture (REDCap)-A metadata-driven methodology and workflow process for
366		providing translational research informatics support. J Biomed Inform 2009; 42: 377-
367		81.
367 368	17	
	17	81.